拨康视云全球创新眼科药物CBT-001国际多中心III期临床试验完成全部患者入组
Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 […]
拨康视云治疗血管化睑裂斑创新药CBT-004在美国完成临床II期实验
Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The […]
拨康视云及参天制药宣布就翼状胬肉创新药CBT-001签订授权协议
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium 6 August 2024 – Osaka, Japan – Santen Pharmaceutical Co., Ltd. (head office: Osaka, Japan; hereinafter Santen), a specialist in ophthalmology, and Cloudbreak Pharma Inc. (head office: California, US; hereinafter Cloudbreak), a clinical stage ophthalmic drug company, announce the […]
